Navigation Links
Scientists question fisheries health test
Date:11/24/2010

A measure widely advocated as a means of assessing the health of marine ecosystems is an ineffective guide to trends in biodiversity, and more direct monitoring is needed, a new study has found. The findings published this week in Nature followed an examination of whether changes in fishery catches reflect changes in the structure of marine food webs, and therefore are a suitable guide to assess the impacts of fishing on marine ecosystem health.

CSIRO Wealth from Oceans Flagship scientist, Dr Beth Fulton, and Dr Sean Tracey from the Tasmanian Aquaculture and Fisheries Institute at the University of Tasmania, were members of the international team involved in the study.

"Biodiversity indicators are used to track the impacts of fishing as a guide to management effectiveness," Dr Fulton said.

"The most widely adopted indicator of biodiversity in the ocean at a global scale is the 'average trophic level' (position in the food chain) determined from fishery catches.

"This is intended to detect shifts from high-trophic-level predators such as Atlantic cod and tunas to low-trophic-level fish, invertebrates and plankton-feeders such as oysters." Dr Tracey said the study was the first large-scale test of whether average trophic level determined by fishery catch is a good indicator of ecosystem average trophic level, marine biodiversity and ecosystem status.

"We looked at average trophic level determined from a range of sources including global fishery catches, long-term surveys, stock assessments and complex computer modelling for marine ecosystems around the world," Dr Tracey said.

"In contrast to previous findings, which reported declines in catch average trophic level thought to be due to the loss of large fish and the increasing catch of small fish, we found that catches are increasing at most levels of marine food webs and that the average trophic level has actually increased in the past 25 years.


'/>"/>

Contact: Bryony Bennett
bryony.bennett@csiro.au
61-362-325-261
CSIRO Australia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists clock on to how sunlight shapes daily rhythms
2. Scientists discover genes linking puberty timing to body fat in women
3. Bacteria use toxic darts to disable each other, according to UCSB scientists
4. Scientists question indicator of fisheries health, evidence for fishing down food webs
5. Scientists learn more about how kidneys fail and how new drugs may intervene
6. Scripps Research scientists identify new mechanism regulating daily biological rhythms
7. Caltech scientists describe the delicate balance in the brain that controls fear
8. UNC scientists identify cellular communicators for cancer virus
9. Scientists discover how the songbirds brain controls timing during singing
10. Scientists pinpoint key defense against parasite infection
11. McMaster scientists turn skin into blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... in how organisms grow and flourish, but studying their ... difficult. Now, a team of chemists and neurobiologists led ... Erin M. Schuman at the California Institute of Technology ... protein synthesis in specific locations. , The new method, ...
... at the University of Chicago show how the bacteria that ... how, by slightly altering one of the microbe's tools, the ... vaccine. , Both papers -- one published online July 28 ... Infection and Immunity -- focus on aspects of the type-III ...
... greatly benefit crop plants, scientists have deciphered the genome ... from diseases. , The research provides clues to better ... safeguards roots and seeds from infection by harmful microbes ... published in Nature Biotechnology and was scheduled to be ...
Cached Biology News:Protein synthesis can be controlled by light, opening way for new scientific, medical applications 2Protein synthesis can be controlled by light, opening way for new scientific, medical applications 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 2Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 4Genome study of beneficial microbe may help boost plant health 2
(Date:5/26/2015)... 2015  Alere Inc. (NYSE: ALR ) (the "Company") ... timely file its Quarterly Report on Form 10-Q for the ... has received a notice from the New York Stock Exchange ... the NYSE,s continued listing requirements under the timely filing criteria ... The reason for the delay relates to ...
(Date:5/26/2015)... 2015   PDI , a leader in ... Oakwood Healthcare in Dearborn, Mich. ... in Delivering the Difference , ... in building collaborative relationships between infection prevention (IP) ... Oakwood Healthcare,s infection preventionist, ...
(Date:5/26/2015)... ANGELES , 26. mája 2015 ... v mene svojej rodiny prezidentom Barackovi Obamovi a ... v súvislosti so stratou Dr. Rongxiang Xu ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol ... dobe a jeho odhodlanie v oblasti vedy a ...
(Date:5/26/2015)... Fluorinov Pharma (Fluorinov), a FACIT portfolio company, today announced ... its Board of Directors.  His appointment strengthens Fluorinov,s leadership ... accelerates its clinical development activities.  "On ... to welcome Luke to the Board of Directors.  Luke ... strength and success of multiple organizations," said Malik ...
Breaking Biology Technology:PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, O legende 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... EPS increased 16.0 percent to $0.58 from $0.50 ... amortization of intangible assets from the 2003 spin-off, ... first-quarter 2008- Total net revenues increased 14.4 percent ... increased 21.0 percent to a record $2.3 billion- ...
... - Results to be Presented at World ... AB announced today that it has completed its open Phase ... nephropathy, a,glomerulonephritis leading to end-stage renal disease. Nefecon is an ... in the kidneys through suppression of the gut immune,system. , ...
... and safety agencies are unable to cope with the ... nanotechnology. The nation needs a new agency to address ... health and environmental impacts of the technically complex products ... landmark paper, Oversight of Next Generation Nanotechnology, J. Clarence ...
Cached Biology Technology:Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 2Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 3Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 4Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 5Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 6Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 7Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 8Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 9Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 10Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 11Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 12Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 13Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 14Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 15Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 16Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 17Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 18Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 19Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 20Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 21Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 22Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 23Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) 2Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) 3Former EPA official calls for new environmental and consumer protection agency 2
... COPAS (Complex Object Parametric Analyzer and Sorter) ... bring the advantages of flow cytometry to ... candidates for automated analysis and sorting. ... principles as traditional flow cytometers, but are ...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Biology Products: